Chronic lung disease · promoting growth and development in very low birth weight infants receiving human milk
Supplemental vitamin A showed no clear difference in chronic lung disease (oxygen use at 28 days in survivors) compared with no supplementation (moderate certainty).
2 findings from 1 review
Death or chronic lung disease · promoting growth and development in very low birth weight infants receiving human milk
Supplemental vitamin A probably leads to lower death or chronic lung disease (oxygen use at 28 days) compared with no supplementation (moderate certainty).
2 findings from 1 review
Death before 36 weeks' postmenstrual age · promoting growth and development in very low birth weight infants receiving human milk
Supplemental vitamin A showed no clear difference in death before 36 weeks' postmenstrual age compared with no supplementation (moderate certainty).
1 finding from 1 review
Neurodevelopmental impairment at 18 to 22 months · promoting growth and development in very low birth weight infants receiving human milk
Supplemental vitamin A showed no clear difference in neurodevelopmental impairment at 18 to 22 months compared with no supplementation (low certainty).
1 finding from 1 review
Vasomotor symptoms (all doses) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to lower vasomotor symptoms (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone probably leads to lower unscheduled bleeding (all doses) compared with combined HT (moderate certainty).
1 finding from 1 review
Endometrial cancer · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation; all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Cardiovascular events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cardiovascular events (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cerebrovascular event (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Mortality from any cause (tibolone 2.5 mg/d) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes mortality from any cause (tibolone 2.5 mg/d) compared with combined HT (very low certainty).
1 finding from 1 review
Endometrial cancer · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone probably leads to higher unscheduled bleeding (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation) all doses compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular events · postmenopausal women with or without vasomotor symptoms
1 finding from 1 review
Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cerebrovascular events (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Mortality from any cause (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone showed no clear difference in mortality from any cause (all doses) compared with placebo (low certainty).
1 finding from 1 review
Vasomotor symptoms (tibolone 2.5 mg/d) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to higher vasomotor symptoms (tibolone 2.5 mg/d) compared with combined HT (moderate certainty).
1 finding from 1 review